TY - JOUR
T1 - Outcomes of atezolizumab and bevacizumab for hepatocellular carcinoma
T2 - Does age matter?
AU - Kao, Wei Yu
AU - Su, Chien Wei
PY - 2022/12
Y1 - 2022/12
N2 - Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth most frequent cause of cancer-related deaths in the world.1 Although curative treatment modalities of HCC, including liver transplantation, surgical resection and local ablation therapies, could provide acceptable outcomes, around 50%–60% of patients with HCC will receive systemic therapies eventually.2, 3 Until recently, tyrosine kinase inhibitors sorafenib and lenvatinib have been the mainstay treatment of unresectable HCC, with median overall survival (OS) durations of 11–14 months.4, 5 The combination of atezolizumab and bevacizumab is the first treatment regimen that has been shown to improve OS over sorafenib in patients with advanced-stage HCC, with the updated median OS duration of 19.2 months.6, 7 One recent real-world data from 11 centres in Korea further showed that the treatment efficacy and safety of atezolizumab and bevacizumab combination therapy for HCC were similar to that was reported in the prospective phase 3 clinical trial.8 Hence, atezolizumab plus bevacizumab has been recommended as the first-line standard of care for patients with unresectable HCC currently.2
AB - Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth most frequent cause of cancer-related deaths in the world.1 Although curative treatment modalities of HCC, including liver transplantation, surgical resection and local ablation therapies, could provide acceptable outcomes, around 50%–60% of patients with HCC will receive systemic therapies eventually.2, 3 Until recently, tyrosine kinase inhibitors sorafenib and lenvatinib have been the mainstay treatment of unresectable HCC, with median overall survival (OS) durations of 11–14 months.4, 5 The combination of atezolizumab and bevacizumab is the first treatment regimen that has been shown to improve OS over sorafenib in patients with advanced-stage HCC, with the updated median OS duration of 19.2 months.6, 7 One recent real-world data from 11 centres in Korea further showed that the treatment efficacy and safety of atezolizumab and bevacizumab combination therapy for HCC were similar to that was reported in the prospective phase 3 clinical trial.8 Hence, atezolizumab plus bevacizumab has been recommended as the first-line standard of care for patients with unresectable HCC currently.2
UR - http://www.scopus.com/inward/record.url?scp=85142343894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142343894&partnerID=8YFLogxK
U2 - 10.1111/liv.15434
DO - 10.1111/liv.15434
M3 - Editorial
C2 - 36415175
AN - SCOPUS:85142343894
SN - 1478-3223
VL - 42
SP - 2597
EP - 2598
JO - Liver International
JF - Liver International
IS - 12
ER -